Log in or register to see all Alerts
New HTA Decisions in England
February 2020
Drug name
PLEGRIDY® (peginterferon beta‑1a)
Biogen Idec Ltd
Decision date
Therapeutic area
Neurological conditions
Therapeutic sub area
Multiple sclerosis
Relapsing–remitting multiple sclerosis in adults.
Decision Detail
Peginterferon beta‑1a is recommended, within its marketing authorisation, as an option for treating relapsing–remitting multiple sclerosis in adults.
Clinical evidence was presented for peginterferon beta‑1a from ADVANCE (a phase 3 double-blind randomised placebo-controlled trial) and ATTAIN (a 2‑year blinded follow-up study of peginterferon beta‑1a only, where all people in the placebo arm of ADVANCE switched to peginterferon beta‑1a after 1 year). The committee concluded that it had minor concerns about the generalisability of the ADVANCE and ATTAIN trials. However, overall, it considered that they were appropriate for decision making. The clinical trial evidence showed that the drug slows disease progression and reduces the frequency of relapses when compared with placebo. There is also an indirect comparison suggesting that there are no differences in effectiveness when comparing peginterferon beta‑1a with its main comparators, that is, other beta interferons and glatiramer acetate (several of the results are academic in confidence). However, it involves less frequent injections than other beta interferons, so improves choice for people with relapsing–remitting multiple sclerosis. The cost-effectiveness estimates for peginterferon beta‑1a compared with other treatments for relapsing–remitting multiple sclerosis, such as other beta interferons and glatiramer acetate, are in line with what NICE usually considers a cost-effective use of NHS resources. The results are commercial in confidence because of confidential comparator patient access schemes, so cannot be reported here.